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Major depression (MDD) is associated with cognitive deficits in processing speed
and executive function (EF) following first episode (FE). It is unclear whether deficits
are state or trait related. Studies following FE MDD over longer periods are lacking,
making it uncertain how cognition and symptoms develop after the initial episode. The
present study assessed cognitive function and symptoms 5 years following FE MDD.
In addition, the study explored relationships between MDD symptoms, rumination, and
cognitive deficits with regards to the trait, state, and scar perspective. Twenty-three
participants with previous FE MDD, and 20 matched control participants were compared
on Delis-Kaplan Executive Function System measures of processing speed and EF,
in a 5-year longitudinal follow-up study. Correlations between current symptoms- and
history of MDD, rumination, cognition were investigated. Findings indicated that cognitive
deficits persisted with no clear signs of exacerbation after initial episode. Inhibition
appeared independent of current and previous symptoms of depression. Processing
speed was related to depressive- symptoms and rumination. In conclusion, results
indicated persisting, stable deficits in both EFs and processing speed. Findings further
suggest that depressive symptoms could be related to deficits in processing speed,
indicating state effects. There was limited support for worsening of cognition after initial
episode. Some aspects of EF like Inhibition could show persistent deficits independent
of depressive symptoms indicating trait effects.
Keywords: major depression and executive dysfunction, first episode major depressive disorder, processing
speed, risk factors, rumination, state, trait, scar
INTRODUCTION
Major Depressive Disorder (MDD) is one of the most prevalent and taxing disorders worldwide
(1). Recurrence following first episode MDD are of particular concern (2), with estimate rates up
to 90% in health care seeking individuals (3). Recurrence leaves patients with higher disability,
lower quality of life, affecting everyday functioning (4, 5), and could be incremental (6, 7).
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Residual symptoms are important risk factors in recurrent MDD
(8). Cognitive deficits persisting in remission (9–11), could
contribute to relapse, recurrence, and impaired daily functioning
in MDD (12–14). However, the literature is mixed regarding
whether deficits in executive- (15–17), or lower cognitive
functions persist in remission (11, 18). Hierarchical organization
of neuropsychological function implies that lower processing
tasks are the foundation of higher cognitive functions like EF
(19). Thus, separating EF from processing speed, seems to be
important when investigating cognitive deficits following MDD
(20, 21). How EF and processing speed relate to other residual
symptoms and risk factors in remission from MDD is uncertain
(22, 23), however.
Not everyone with MDD shows cognitive deficits (24).
Differences in risk factors for cognitive deficits could help explain
this, and include: depression status (9, 10, 15, 25), depressive
symptoms (26), number- and length of episodes (11, 27),
comorbid disorders (19, 20, 28, 29), rumination (30). In addition,
comorbidity (31), and rumination [for a recent review see (32)],
have been associated with a more severe course of illness.
According to Allot et al. (22) development of both MDD and
EF occur in parallel in adolescence and early adulthood. Thus,
following a group of young adults from FE MDD reduces risk
factors and moderators like age (33, 34). Moreover, longitudinal
studies investigating FE MDD over longer periods in remission
are lacking (23), precluding how cognition develops following
FE MDD.
Many central issues regarding the neurocognitive profile in
MDD can be illustrated by the state, trait and scar debate [for
a discussion see (23, 35)]. States can be understood as deficits
caused by-, and fluctuating with-, depressive symptoms. There
are mixed findings regarding state effects on EF (11, 17, 26).
Findings are also mixed regarding processing speed (11, 25), but
most authors seem to find a relationship to depressive symptoms
or status (15, 26, 36, 37). Scars are neurobiological changes
due to previous depression or environmental stressors. Scarring
could include length, number, and severity of MDD, resulting
in exacerbated cognitive impairment (22). Neurobiological
changes could also increase risk for further episodes of MDD
(7). In addition to this, common treatments could mediate
changes and further alter neurocognitive function (25, 38).
Scarring effects could be investigated through the relationship
between previous MDD duration and symptom severity, and
later cognitive function (22). Semkovska et al. (11) found
number of episodes negatively influenced attention, processing
speed, verbal fluency, and task shifting, supporting scar effects.
When manifested as traits, impairments are independent of
scars and current symptom states, predating FE MDD. There
seems to be most agreement on persistent deficits in EFs
(15, 25, 36, 39), with mixed findings regarding verbal fluency
(15, 25, 36, 39).
The current study was a 5 year longitudinal study,
investigating EF, inhibition, working memory/mental flexibility,
and verbal fluency, in addition to motor- and processing speed.
Previous studies investigating the FE group found deficits in
EFs and processing speed in the acute phase- (40), and 1
year following FE MDD (41). (41) found lasting impairments
in the EF tasks Inhibition/Switching and verbal fluency. The
current study investigated if deficits and symptoms persisted
or normalized, after 5-years. In addition, the trait, state, and
scar perspective were utilized in exploring the findings. To the
authors knowledge, this is the first study to measure cognition
in a group with FE MDD over 5 years. Consequently, the
study could contribute to an increased understanding of the
longitudinal development of cognitive residual symptoms and
course of illness following FE MDD. The following hypotheses
were investigated:
1) We predict that cognitive deficits persist after 5 years,
and that a group with previous FE MDD will differ from
a matched control-group, on tests measuring both processing
speed and EFs.
2) It is expected that cognitive deficits and rumination
related to depressive symptoms at time of assessment could
represent state effects. Cognitive deficits and symptoms related
previous length and strength of depression, worsening over time,
could represent scar effects. Cognitive deficits that are relatively
stable and independent of current- and previous symptoms
of depression, could represent traits. EF is suspected to be
relatively independent of state and scar effects, and a relationship
between EF and rumination is expected. Processing- and motor




This longitudinal 5-year case control follow-up study examined
a group with FE MDD and matched controls. There were
three points of assessment: Participants were assessed at
baseline in the acute phase of MDD (T1), after 1 year
(T2), and after 5 years (T3). For additional information,
see Figure 1.
Recruitment and Participant Flow
Participants in the depression group (DG) were recruited from
primary healthcare and student healthcare services in Bergen,
Norway. Participants were informed about the ongoing study
through the cooperation of physicians and psychologists in
primary- and university healthcare clinics. A study coordinator
contacted interested patients that met the inclusion criteria at
T1. Initial inclusion criteria were current FE depression of a
moderate- to severe degree, indicated by a score of ≥20 on
the Montgomery Åsberg Depression Rating Scale [MADRS;
(42)]. Initial exclusion criteria for the DG were earlier history-,
treatment-, or diagnosis of depression. Exclusion criteria for
all participants in the DG from T1, T2, and T3 were the
following: Psychosis, electroconvulsive treatment, alcohol- or
substance abuse, brain damage, neurological- or severe somatic
disorder. A trained psychologist assessed exclusion criteria
at each time point by a structured questionnaire (T1, T2,
and T3), and The Norwegian version of Mini-International
Psychiatric structural interview [MINI; (43)] for the DG
(T1 and T2). A control group was recruited, individually
matched on the following variables: Sex, age, and years of
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FIGURE 1 | Participant flowchart.
education (±2 years), and the matching was valid at T3 (see
Table 1). Controls were recruited at the University of Bergen
and through colleges at the Department of Biological and
Medical Psychology. Exclusion criteria for controls were: History
of any mental disorder, alcohol- or substance abuse, brain
damage, neurological- or severe somatic disorder, measured by
a structured questionnaire designed for the study (at T1, T2,
and T3). All participants were invited to a 1-year follow up
assessment (T2) at T1. At the 5-year follow up assessment
(T3), participants were contacted by mail and invited to
take part in the study. Dropouts were largely participants
that the study was unable to contact due to expired contact
information, and participants that had moved away (see
Figure 1).
Clinical Assessments and Rumination
Measures
Clinical assessments were made by trained psychologists. MINI
was used to assess history of psychiatric disorders in the DG
at T1 (version 5.0), and at T3 (version 6.0). All in the DG met
DSM-IV criteria for MDD as measured by MINI. Depressive
symptoms were measured by MADRS at all time points. At T3 a
retrospective assessment of relapse-, recurrence, and duration of
MDD was done using the National Institute of Mental Health’s
Life Chart Method [NIMH LCM; (44)]. The LCM was used to
measure relapse and asses months of depression in the DG since
T2. Relapse was defined as reporting one or more depressive
episode since T2. Structured interviews were done in the DG
assessing exclusion criteria, the use of psychotropic medication
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and psychological treatment. Controls were not assessed by
clinical interviews or MADRS, as psychiatric disorders were
exclusion criteria in this group.
Both the DG and controls completed self-report assessments
of depressive- and neurotic rumination at both T2 and T3.
Depressive rumination was measured by the Norwegian version
of the Ruminative Responses Scale [RRS; (45)], a 22 item four
point likert questionnaire that measures ruminative responses
to depressive mood. The Norwegian version of the 12 item
five point likert rumination subscale of Rumination-Reflection
Questionnaire (RRQ) measured rumination independently of
depressive mood. This form of self-rumination is associated with
the personality trait neuroticism (46, 47). At T2 RRS was only
administered to the DG. RRQ was administered in both groups
at T2 and T3 (see Table 1).
Clinical Profile
Participants differed in how their course of illness developed
following FE MDD. At T3 symptom severity as measure
by MADRS ranged from not depressed <12 (n = 16), to
mild- 12–22 (n = 5), and moderate symptoms 23–29 (n
= 2) as indicated by the Norwegian MADRS manual (48).
Seventeen patients had one or more episodes of relapse (74%)
between T2 and T3. Almost half of the group (n = 11) had
histories of comorbid psychiatric symptoms as assessed by
MINI at T1 and T3, hereunder: Generalized Anxiety Disorder,
Panic Disorder With- and Without Agoraphobia, Agoraphobia,
Obsessive Compulsive Disorder, and Social Phobia. There were
no instances of exclusion criteria as assessed by MINI; neither
Psychotic Disorder nor Alcohol- or Substance Abuse. At T3 four
patients were using psychotropic medication: One was currently
TABLE 1 | Demographics and clinical measures.
Demographics and Depression group Control group
clinical measures for n = 23 (11/12) n = 20 (9/11)
T3 groups (M/F)
M (SD) M (SD)
Age 30.34 (5.74) 30.45 (6.09)
Education 15.34 (2.34) 16.6 (2.01)
IQa 118.65 (8.47) 119.7 (8.27)
Age of onset MDD 25.61 (5.73)
T2 RRSb 45.49 (11.89) n = 22
T3 RRS*** 48.43 (13.31) 30.15 (9.74)
T2 RRQ*** 44.90 (8.99) n = 20 30.26 (7.26) n = 19
T3 RRQ*** 42.13 (12.52) 32.40 (8.02)
T1 MADRSb 24.43 (3.8)
T2 MADRSb 10.27 (5.64) n = 22
T3 MADRSb 8.87 (8.13)
Months depressed since T2 12.60 (14.45) n= 21
M, Mean; SD, Standard Deviation; M/F, Males/Females; n, Number of participants; IQ,
Intelligence Quotient. ameasured at inclusion ***Significantly different between groups p
< 0.001, RRS, Ruminative Responses Scale; RRQ, Rumination-Reflection Questionnaire
(Rumination subscale); MADRS, Montgomery Aasberg Depression Rating Scale; bCG
were not assessed.
using a Selective Serotonin Reuptake Inhibitor medication
(SSRI: Escitalopram), while two were using Selective Serotonin-
Noradrenalin Reuptake Inhibitors (SNRI: Venlafaxine). Finally,
one participant was prescribed a sedative (Chlorprothixene:
Truxal). The same patients were also receiving psychological
treatment and outpatient psychiatric follow up. One patient
was currently in psychotherapy, while three were in contact
with the District Psychiatric Center for outpatient follow up of
psychotropic mediation and/or psychotherapy (see Table 1 for
more clinical characteristics).
Ethics and Compensation
All participants gave informed consent to participate in the
study. Participants received a gift card valued at 400 Norwegian
Kroner (∼50 United States Dollars) for their participation. The
study was approved by the Regional Committee for Medical
and Health Research Ethics and was performed in accordance
with the World Medical Associations Declaration of Helsinki
regarding Ethical Principles for Medical Research Involving
Human Subjects (49).
Neuropsychological Assessment
Neuropsychological testing took place at the University
outpatient clinic for neuropsychology at all points of assessment.
Experienced test technicians did the neuropsychological
assessment. IQ was measured at inclusion (T1) by Wechsler
Abbreviated Scale of Intelligence [WASI; (50)]. Participants
completed a battery of standardized neuropsychological tests at
all time points. EF and processing speed were assessed by Delis
et al. (51) Delis-Kaplan Executive Function System (D-KEFS).
Three subtests from the battery were investigated: The Color
Word Interference Test (CWIT) measuring processing speed,
inhibition, switching and general EF (21), the Verbal Fluency
Test (VFT), and the Trail Making Test (TMT) measuring
motor- and processing speed, as well as switching (52). See
Supplementary Materials 1 for description of tasks.
Contrast-, composite-, and error scores were computed based
on descriptions in the D-KEFS manual (51), and previous
studies (41). Contrast scores were made to separate EFs from
processing speed, subtracting the Color Naming and Word
Reading conditions from the Inhibition- [Inhibition Contrast
= Inhibition – (Color Naming + Word Reading)/2], and
Inhibition/Switching conditions [Inhibition/Switching Contrast
= Inhibition/Switching – (Color Naming + Word Reading)/2].
An EF composite score was for the CWIT overall by separating
the processing speed- from the EF conditions [CWIT Executive
function composite = (Inhibition + Inhibition/Switching)/2 –
(Color Naming + Word Reading)/2]. To separate processing
speed and lower cognitive processes from EF, contrast scores
for TMT Number-Letter Switching were calculated [Contrast
Number-Letter Switching = Number-Letter Switching – (Visual
Scanning + Letter Sequencing + Number Sequencing + Motor
Speed)/4]. Error scores were pooled for the different D-KEFS
tests. In addition, CWIT error scores were pooled to represent
executive dysfunction in the Inhibition and Inhibition/Switching
conditions, and processing deficits in the Color Naming and
Word Reading conditions.
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Data Scoring and Analysis
All statistical analyses were performed in Statistical Package for
the Social Sciences (SPSS version 25). Raw scores, that consisted
of seconds to complete task (CWIT, TMT, high score = poor
performance), and words generated per minute (VFT, high score
= good performance), were used for the neuropsychological tests.
Variables were plotted and checked for linearity and outliers.
Outliers were inspected and determined to represent real scores
and not errors. Normality was assessed using Kolmogorov-
Smirnov test of normality and non-parametric tests were used
when assumptions were violated. Cohen (53) was used to describe
effect sizes as small, medium and large.
Differences Between the DG and Controls in
Cognitive Function Over Time
Mixed between-within subjects ANOVA was used to calculate
differences between groups in cognitive function and change
over the three points of assessment (Group × Time × D-
KEFS conditions). Box’s test of equality of Error Variance and
Mauchly’s Test of Sphericity was performed and Multivariate
statistics reported when the latter assumption was violated.
Levenes test of Equality of Error Variances was performed for all
ANOVA analyses, and Welch values given when this assumption
is violated. One participant in the DGwas only available at T1 and
T3 and was thusmissing from theMixed between-within subjects
ANOVA, and other analyses containing data from T2 (see
Figure 1). Groups at T3 were compared by one-way analysis of
variance (ANOVA) on matched variables and clinical measures.
Mann Whitney U-tests were used to assess differences between
groups on non-parametric data, and independent samples chi
square tested for categorical variables. Change scores were
calculated by subtracting D-KEFS scores at T2 from D-KEFS
scores at T3. Negative values implied decreased performance over
time (with the exception of VFT, were the opposite was the case).
Paired sample t-tests were used to assess changes on D-KEFS by
comparing scores from T2 to scores from T3 in the DG, and the
control group.
Separating EF and Processing Speed
One-way ANOVA analyses were used to investigate differences
between groups on the different D-KEFS conditions and contrast
scores at T3. Man Whitney U-tests were used to assess error
scores and the CWIT EF composite score. Effect size measures
(η2) for Man Whitney U-tests were calculated through the
following formula (η2 = Z2/N-1).
Traits, States, and Scars, Relationships Between
Depression, Rumination, and Cognitive Function
Bivariate correlation coefficients were calculated to explore
relationships at T3. The relationship between symptoms of
MADRS, RRS, RRQ, and D-KEFS scores was investigated.
Spearman’s Rho was used as a non-parametric alternative to
Pearson’s correlation coefficients when assumptions for the
latter were not met. To separate depressive state (MADRS T3)
from scar effects, an explorative composite score consisting
of a standardization (Computed in SPSS) of number of
months depressed (Z-score months depressed), combined
with standardized MADRS scores before T3 (T1, T2) were




Groups did not differ significantly (p > 0.05) on any of the
matched variables sex, age, and years of education, nor in IQ (see
Table 1 for means and frequencies).
Differences Between the DG and Controls
in Cognitive Function Over Time
Mixed between-within subjects ANOVA found a significant
interaction effect for Time × Condition in all D-KEFS tests
(see Table 2). Means indicated that scores from T1 improved.
A lack of a Time × Condition × Group interaction supported
that improvements did not differ between groups, and that
TABLE 2 | Cognitive differences between groups over time.
Main effects Interaction effects
Group Condition Time Time × group Time × condition Condition × group Time × cond. × group
CWIT Wilk’s λ 0.035 0.501 0.918 0.594 0.869 0.910
F (df) 13.55 (1, 40) 347.96 (3, 38) 19.34 (2, 39) 1.75 (2, 39) 3.99 (6, 35) 1.906 (3, 38) 0.58 (6, 35)
Partial eta-sq. 0.253 0.965 0.131 0.082 0.406 0.131 0.090
F-sig. p = 0.001 p < 0.001 p < 0.001 p = 0.188 p = 0.004 p = 0.131 p = 0.74
VFT Wilk’s λ 0.035 0.772 0.968 0.759 0.918 0.971
F (df) 3.48 (1, 40) 534.53 (2, 39) 5.57 (2, 39) 0.653 (2, 39) 2.93 (4, 37) 1.751 (2, 39) 0.28 (4, 37)
Partial eta-sq. 0.08 0.965 0.228 0.032 0.241 0.082 0.029
F-sig. p = 0.069 p < 0.001 p = 0.006 p = 0.526 p < 0.05 p = 0.19 p = 0.89
TMT Wilk’s λ 0.085 0.559 0.953 0.446 0.791 0.898
F (df) 6.53 (1, 40) 99.53 (4, 37) 15.41 (4, 39) 0.953 (2, 39) 5.12 (8, 33) 2.45 (4, 37) 0.469 (8, 33)
Partial eta-sq. 0.140 0.915 0.441 0.047 0.554 0.209 0.102
F-sig. p = 0.015 p < 0.001 p < 0.001 p = 0.39 p < 0.001 p = 0.063 p = 0.87
CWIT, Color Word Interference Test; VFT, Verbal Fluency Test; TMT, Trail Making Test; (df), degrees of freedom; Partial Eta-sq., Partial Eta Squared.
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TABLE 3 | Cognitve performance at T3.
Groups at T3 (M/F) Depression group n = 23 (11/12) Control group n = 20 (9/11) Statistics
D-KEFS measure M (SD) Change score from T2 n = 22 M (SD) Change score from T2 F(1,41) p eta sq.
Color word interference test
Color naming 29.87 (4.68) −0.55 26 (4.63) 0.5 **7.37 <0.01 0.152
Word reading 22.52 (3.3) 0.5 18.9 (2.43) 0.95 ***16.37 <0.000 0.285
Inhibition 48.04 (8.28) −0.95 41 (5.91) 0.1 ***10.02 <0.001 0.196
Inhibition/switching 56.13 (7.52) −0.41 48.65 (9.58) −1.05 ***8.22 <0.001 0.167
Inhibition contrast 21.85 (6.38) −0.52 18.55 (5.57) −0.625 3.13 0.084 0.071
Inhibition/switching contrast 29.93 (5.64) −0.52 26.2 (8.29) −1.78 3.05 0.088 0.069
Verbal fluency
Letter fluencyhs 50.78 (11.48) −1.27 55.2 (10.51) −0.4 1.71 0.198 0.040
Category fluencyhs 48.48 (10.18) 0.27 51.75 (9.68) 3.1 1.16 0.288 0.027
Category switchinghs 14.96 (2.2) 0.32 15.4 (2.32) 0.65 0.41 0.527 0.010
Trail making test
Visual scanning 17.91 (4.5) 0.5 15.25 (2.88) 1 *5.15 0.029 0.112
Number sequencing 24.04 (8.47) 1.95 17.3 (4.92) 2.55* **9.78 0.003 0.193
Letter sequencing 24.17 (8.95) −1.5 17.2 (3.37) 2.55 **10.78 0.002 0.203
Number letter switching 62.96 (18.95) 0.045 50.1 (15.26) 2.65 *5.88 0.02 0.126
Motor speed 20.13 (9.68) −0.86 16.8 (5.02) 1.45 1.91 0.174 0.045
Contrast number letter switching 41.39 (15.33) 0.02 33.46 (14.43) 0.76 3.02 0.09 0.069
M/F, Males/Females; n, Number of participants; M, Mean (seconds to complete task, except for verbal fluency); SD, Standard Deviation; Df, Degrees of freedom *p < 0.05, **p < 0.01,
***p < 0.001, hshigh score indicate high performance in these conditions (words generated).
both processing speed and EF improved similarly over time. In
addition, there was a significant main effect of group on the
CWIT and TMT, while the VFT only approached significance,
with a medium effect size. Overall, groups showed similar
improvements, but differed in test performance.
One-way ANOVA tests indicated no significant differences
between groups on change scores from T2 to T3. This was
supported by paired sample t-tests on D-KEFS scores from T2
to T3, that showed there were no significant improvements
in scores, with the exception of controls improving on TMT
Number Sequencing from T2 (see Table 3). In sum, this
supported that the Time × Condition interaction above was due
to changes from T1 to T2, not from T2 to T3. Cognitive deficits
persisted after 5 years and were relatively stable following the
acute phase of FE MDD.
One-way ANOVA tests investigated which of the cognitive
functions measured by D-KEFS, processing speed or EF, showed
largest differences between groups (see Table 3). The DG
performed significantly poorer than controls in all the conditions
of the CWIT at T3. The contrast scores for Inhibition and
Inhibition/Switching were not significantly different, although
differences showed moderate effect sizes. There were significant
differences in all the conditions of the TMT, except Motor
Speed. The Number-Letter Switching contrast score approached
significance, with amoderate effect size. There were no significant
differences in the VFT conditions with small effect sizes. Groups
significantly differed in conditions measuring both EF and
processing speed, but not motor speed. Contrast scores were not
significantly different.
Separating EF and Processing Speed
A significant difference between the groups was found on a
composite score for Inhibition and Inhibition/Switching, with
the DG performing poorer (M = 25.89, Mdn = 27.5, n = 23)
than controls (M = 22.38 Mdn = 22.75, n = 20) U = 146.5,
p = 0.023, η2 = 0.099. Error scores from the two processing
speed conditions were also compared to the executive conditions.
Errors in the processing speed conditions differed with the DG
making more errors (M = 0.87, Mdn = 1), and controls fewer
(M = 0.25, Mdn = 0), Mann Whitney U = 150.5, p = 0.023, η2
= 0.123. The DG made more errors in the executive conditions
(M = 2.13, Mdn = 2), compared to controls (M = 0.85, Mdn
= 0.50), Mann Whitney U = 92, p = 0.001, η2 = 0.286. No
significant differences in error scores appeared in either VFT
or TMT. Differences in composite score and errors in the EF
conditions of CWIT, supported deficits in EF when controlling
for processing speed.
Course of Illness
Overall, symptoms of depression and rumination were relatively
stable in the DG after T1 (see Table 1). The standard deviation
of MADRS and months depressed at T3 suggested increased
variance of depression in the DG, however. This could reflect
a polarization of depressive symptoms in the group. Comorbid
disorders increased in the group. At T1 only (16%) had a history
of comorbid disorders (one of these dropped out). At T3 (48%)
had a history of comorbid disorders. McNemar’s test showed that
increased comorbidity was significantly greater than chance from
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1 MADRS 1
2 RRS 0.541** 1
3 RRQ 0.305 0.810** 1
4 CWIT: color naming 0.341 0.174 0.141 1
5 CWIT: word reading 0.528** 0.426* 0.155 0.512* 1
6 CWIT: inhibition 0.049 0.037 0.217 0.671** 0.313 1
7 CWIT:
inhibition/switching
0.363 0.241 0.242 0.656** 0.581** 0.357 1
8 CWIT: inhibition
contrast
−0.164 −0.076 0.223 0.398 −0.003 0.877** 0.014 1
9 CWIT: Inh/switching
contrast
0.182 0.104 0.169 0.266 0.222 0.044 0.847** −0.224 1
10 VFT: letter fluency −0.063 0.203 0.252 0.135 −0.236 0.147 0.09 0.227 0.152 1
11 VFT: category
fluency
−0.424* −0.362 −0.101 −0.022 −0.500* 0.058 −0.02 0.204 0.09 0.578** 1
12 VFT: category
switching
−0.26 −0.231 0.164 0.03 −0.285 0.35 −0.127 0.518* −0.159 0.144 0.591** 1
13 TMT: visual scanning 0.551** 0.137 0.053 0.548** 0.464* 0.388 0.649** 0.088 0.430* −0.243 −0.247 −0.168 1
14 TMT: number
sequencing
0.521* 0.264 0.088 0.509* 0.457* 0.335 0.591** 0.032 0.420* 0.183 −0.121 −0.167 0.667** 1
15 TMT: letter
sequencing
0.545** 0.171 0.034 0.560** 0.387 0.15 0.443* −0.025 0.199 0.002 −0.029 0.119 0.550** 0.457* 1
16 TMT: number-letter
switching
0.489* −0.088 −0.246 0.580** 0.244 0.331 0.376 0.1 0.221 0.055 0.025 0.024 0.538** 0.662** 0.681** 1
17 TMT: motor speed 0.239 0.096 0.009 0.369 0.539** 0.178 0.550** −0.165 0.434* −0.292 −0.275 −0.357 0.470* 0.402 0.186 0.31 1
18 TMT: N-L switching
contrast
0.308 −0.192 −0.344 0.487* 0.09 0.301 0.157 0.154 0.031 0.079 0.097 0.083 0.34 0.472* 0.566** 0.946** 0.124 1
*p < 0.05 (2-sided), **p < 0.01 (2-sided), MADRS, Montgomery Aasberg Depression Rating Scale; RRS, Ruminative Responses Scale; RRQ, Rumination-Reflection Questionnaire
(Rumination subscale); CWIT, Color word interference test; VFT, Verbal Fluency Test; TMT, Trail Making Test.
Bold values represent potential state effects.
T1 to T3, p = 0.039 (2-sided), in the DG. This could indicate
considerable heterogeneity regarding course of illness after T1.
Relationships Between Symptoms and
Cognitive Function
Spearman’s Rho was calculated to explore the relationship
between depressive symptoms and D-KEFS scores at T3 (see
Table 4). MADRS showed small to large correlations with
CWIT scores. Word Reading showed the largest relationship
to MADRS. Relationships between EF (CWIT contrast and
composite scores) and T3 MADRS score was small. There were
small to medium relationships between CWIT and depressive
rumination, showing similar, but smaller relationships than
MADRS. MADRS showed a large relationship to depressive
rumination supporting this. The CWIT processing speed
measures showed small correlations to neurotic rumination.
RRQ showed a moderate relationship to Inhibition/Switching,
r= 0.34 n = 23 p = 0.112 (2-sided), although this relationship
was smaller on the contrast score r = 0.303 n = 23 p = 0.116
(2-sided). CWIT processing speed measures showed the largest
relationships to depressive- symptoms and rumination. Neurotic
rumination differed, showing only a moderate relationship
to Inhibition/Switching.
State Effects VFT and TMT
T3 MADRS showed small to medium relationships to VFT.
Category Fluency showed the largest correlation (see Table 4).
There were similar but smaller relationships to RRS, and only
small relationships to neurotic rumination. MADRS showed
small to large correlations with TMT. Most of the processing
speed measures showed large relationships to MADRS. TMT
Letter Sequencing showed the largest association with MADRS.
TMT showed mostly small relationships to both types of
rumination. One exception was for the TMT Number-Letter
Switching contrast score, that showed a negative moderate
relationship with RRQ r = −0.3 n = 23 p = 0.108 (2-sided).
Category fluency and the processing speed measures of TMT
showed strongest relationships to depressive symptoms. Neurotic
rumination showed amoderate negative relationship to Number-
Letter Switching contrast score.
Frontiers in Psychiatry | www.frontiersin.org 7 December 2020 | Volume 11 | Article 575867
Ronold et al. Longitudinal Assessment of Major Depression
Scar and Trait Effects
The scar composite score was used to investigate how previous
history of depression related to D-KEFS scores and rumination
at T3. The scar composite showed small correlations to all of
the CWIT scores except for the CWIT Inhibition/Switching
condition, with a moderate correlation r = 0.439 n =
23, p= 0.036 (2-sided), and an even stronger relationship to
the Inhibition/Switching contrast score r = 0.486 n = 23, p
= 0.019 (2-sided), indicating that this relationship could not
be explained by processing speed. The scar composite showed
a large correlation to RRQ at T3 r = 0.562, n = 23, p =
0.005 (2-sided), higher than to current depressive symptoms (see
Table 4), which could suggest that neurotic rumination show
larger relationship to MDD over time than current depressive
symptoms. Differences between the DG and controls in CWIT
error scores were new, and could thus represent a scar effect.
Error scores on the CWIT, especially errors in the EF conditions,
showed weak relationships to the scar composite, rho = −0.064
n = 23, p = 0.773 (2-sided) in addition to MADRS at T3 rho =
−0.073 n= 23, p= 0.742 (2-sided), however. The scar composite
was related to Inhibition/Switching and neurotic rumination at
T3, but not new differences between groups CWIT error scores.
Traits, Stable Differences Between DG and
Controls That Are Unrelated to State and
Scar Measures
The CWIT Inhibition contrast score showed small correlations
to both state- rho = −0.164, n = 23, p = 0.454 (2-sided), and
scar measures of depression, rho= −0.069 n= 23, p= 0.753 (2-
sided). It did, however, show amedium correlation to error scores
in the executive condition, rho = 0.451, n = 23, p = 0.031, thus
EF errors could be related to a trait EF/Inhibition impairment
independent of state- and scar effects. CWIT Inhibition score
differed between the DG and controls at both T1, T2 and T3,
and show negligible relationships to both the scar composite r =
0.059 n= 23, p= 0.788, and MADRS at T3 rho= 0.049 n= 23, p
= 0.825 (2-sided), and a comparable relationship to error scores
in the EF conditions rho = 0.382 n = 23, p = 0.072 (2-sided).
In conclusion, there is some support for stable deficits in CWIT
Inhibition that could be independent of state- and scar effects,
which thus could represent a cognitive trait deficit in MDD.
DISCUSSION
The main aim of the present study was to investigate cognitive
residual symptoms in the first longitudinal 5-year follow up study
of FE MDD. In addition, relationships between current- and
previous depression, current rumination, and cognitive deficits
were also explored. It was expected that stable deficits, unrelated
to current and previous MDD history, could represent traits.
Persisting Deficits
The first hypothesis predicted that cognitive deficits would persist
after 5 years. This hypothesis was supported. Results suggested
that there are broad, relatively stable deficits on most of the
cognitive measures. Stable differences are in line with several
reviews and meta-analyses showing that cognitive deficits persist
in remission (9, 11, 15, 36). However, this is the first study to
show deficits 5 years following FEMDD. Importantly, there were
no indication of significant cognitive decline after initial episode,
and therefore little support for a worsening of cognition during
the 5 years, although the study could be underpowered to detect
small changes.
Deficits in EF and Processing Speed
Current findings support cognitive deficits in both EF and
processing speed, in line with the first hypothesis. Although there
were larger effect sizes for differences in the latter, there was also
moderate effects for differences in EF contrast scores controlling
for processing speed. The lack of significant differences in motor
speed, also suggest that motor slowing is not sufficient to explain
differences on the tests (16, 21). Persisting deficits in EF, even
when controlling for processing speed, is mostly supported.
This could be contrary to Semkovska et al. (11), were the
authors suggest that executive dysfunction is due to deficits in
processing speed. Deficits in processing speed showed the largest
effects, however.
Course of Illness and Cognition
Table 1 indicated that the DG differed in their rate of depression
following first episode (large standard deviations), which could
influence results. In addition, the increase in comorbidity could
influence cognitive function and has been shown to have a
relationship to processing speed (20), but not inhibition (54).
Of note, there was no indication of significant worsening in
cognitive functions after T1, and therefore limited evidence to
support cognitive exacerbation from the increase in comorbidity.
The study could be underpowered to detect this, however. The
increase could illustrate the need for longer follow up times
in clinical studies, as comorbidity commonly increase with
increasing follow up time (31). The relatively high depressive
rumination could indicate that rumination represent risk factor
in remission from MDD (32, 55, 56). Residual symptoms
like rumination, and risk factors like comorbid disorders,
could thus be of importance when planning treatment and
prevention strategies. The majority of patients had undergone
psychological- and/or pharmaceutical treatments, that could
have influenced neurocognitive function (25, 38). However, some
authors have suggested that at least some cognitive deficits persist
despite “successful” treatment (39), as indicated the current
study, and thus new interventions targeting cognitive functions
seem warranted.
Are Deficits Associated With Depressive
Symptoms States, Scars, or Traits?
There was mixed support for the hypothesized state, scar, and
trait effects. Preliminary results supported the hypothesis that
processing speed deficits are influenced by state effects. In
addition, this finding is in accordance with meta-analyses and
reviews showing relationships between MDD and processing
speed deficits (26, 37). Similar, albeit weaker, relationships were
found between depressive symptoms, depressive rumination,
and cognitive tests. This could suggest that the relationship
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between depressive rumination and cognitive function is due
to depressive symptoms in the current sample. The small
relationships between depressive rumination and EF went
contrary to our expectations. Recent meta-analyses, however,
support small relationships between EF and rumination (57–59).
Of note, neurotic rumination at T3 showed different associations
to cognitive tests, and stronger relationships to EF, compared to
depressive rumination. Inhibition and switching were related to
neurotic rumination, in support of our hypothesis. Switching,
an EF, somewhat unexpectedly showed a moderate negative
relationship to neurotic rumination, although some studies
have found relationships between rumination and better scores
on some aspects of EF (60). Alternatively, this could be a
spurious relationship. In conclusion, measuring different forms
of rumination (61), like neurotic rumination, could probably
further elucidate on the relationship between rumination
and cognition.
The exploratory scar composite score showed a relationship to
Inhibition/Switching. There was no relationship between the scar
composite and contrast score for Inhibition. This could indicate
a scar effect on mental flexibility, although this finding must
be taken with caution, as there was no clear indication for a
worsening of cognitive functions over time. Thus, there is limited
support for the scar hypothesis in the present study. Age and
follow-up time could explain this however: 5-years might be too
short, and participants to young, for a scaring effect to appear.
Neuropsychological exacerbation caused by depression could
probably be more apparent with increasing age (33). Semkovska
et al. (11) found evidence for exacerbation of cognition with
number of depressive episodes, although this finding could be
influenced by age as well. However, it is hard to conclude about
scar effects without measuring cognitive functions before onset
of FE MDD.
Of note, neurotic rumination correlated with both the
scar composite and Inhibition/Switching. Surprisingly, the
relationship between neurotic rumination and history of
depression, was higher than that to current depressive symptoms.
This could suggest that neurotic rumination is a risk factor
for-, or at least associated with MDD history. It could be that
neuroticism/rumination and Inhibition/Switching are a part of
risk factors for MDD over time. The former could support
emerging perspectives for understandingmental illness that focus
on neuroticism like the p-factor model (62), while the latter is
supported by Schmid and Hammar (41), that found relationships
between Inhibition/Switching and relapse and recurrence in
a FE sample. Differences between the DG and controls in
CWIT error scores are new and could thus represent a scar
effect, but was not related to the scar composite. The scar
composite is a novel construct based on theoretical assumptions
[see Figure 1 in (22)], and might imperfectly capture the
nature of the depressive history in our sample, however. In
conclusion, there is insufficient evidence in the current paper
to conclude regarding the scar hypothesis. Finally, neurotic
rumination and Inhibition/Switching could be related to history
of depression.
Inhibition, although significantly different between the DG
and controls during the 5 years, did not show any sizable or
significant relationships to history- or symptoms of depression
nor rumination. All this could indicate that inhibition represent
a trait and a cognitive risk factor in a group with recurrent
depression. The EF function of Inhibition is recognized in other
longitudinal studies as a stable deficit in MDD (63–65), in
addition to several meta-analyses (9, 17, 36, 37). Inhibition is
also the function most strongly associated with the unity EF
factor (66), which could point toward a general persisting EF
impairment as a trait associated with recurrent MDD.
Strengths and Limitations
This was the first study to investigate cognition in FE MDD
after 5 years. Thus, the study could contribute with a unique
perspective on the development of MDD. The current study
is important due to the considerable length of follow-up time
making it able to assess change and stability in cognitive
function in relation to symptoms and course of illness. The
thorough neuropsychological testing enabled differentiation
between processing speed and EF. In addition, symptoms
were measured at different time points, making it possible
to investigate longitudinal relationships between cognition and
symptoms. Furthermore, the study points to several variables
which are relevant for further research, like persisting cognitive
deficits (neurotic) rumination, and increased rate of comorbidity
following the FE MDD. The increase in comorbidity, however,
entails that the study did not assesMDD alone, but also comorbid
disorders. This might more accurately reflect the common
courses of illness and thus enhance the ecological validity of the
current study, but also potentially confound results as discussed
above and below. Future studies with larger samples should
investigate how risk factors like comorbidity, rumination, relapse,
and different treatments mediate and moderate cognition and
course of illness in MDD.
Despite some strengths, the study also had major limitations.
The results were from a small sample, and a selected group. All
participants in the DG were outpatients. IQ was in the average
to above average range which could mask deficits. However,
the DG and controls showed comparable IQ scores and the
groups did not differ on matched variables. MINI does not
measure personality pathology (other than antisocial personality
disorder) which could have been present- and influenced
results. In addition, comorbidity, depressive symptoms, and
treatment effects, could have confounded results. Dropout was
also considerable. Interestingly, dropout was higher in the control
group, which could suggest that clinically unrelated factors
played a part in this. Many participants were students that
moved away after completing university. The lack of clinical
assessments of the controls could be viewed as a major limitation.
Symptoms in the control group could have influenced results,
but the relatively low rumination scores at T3 (see Table 1)
suggested that this was not a major issue, however. There were
also issues regarding measurements and sample size. Given
the long follow up time, the assessments of months depressed
could be influenced by subjective memory and is probably not
completely accurate, which could have influenced the novel
scar composite. Due to increased type II error rate Bonferroni
adjustments were not made to significance levels. This could
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have increased false positive findings. In addition, the study
could be underpowered to detect small changes over the 5 years,
which could have resulted in the lack of support for scarring
effects. In addition, correlations and other effect sizes might
be unstable and inflated due to the small sample (67), and
should be interpreted with caution. Results should be considered
preliminary and should be replicated in larger samples [for a
discussion see (68)]. Also, importantly, correlation does not
imply causation, thus the current study cannot say anything
about the direction of the relationship between symptoms and
cognition. Future studies should longitudinally investigate risk
factors in larger samples, making it possible to use more complex
statistics to causally model relationships between variables, like
in structural equation models. Furthermore, several measures
of EFs should be included to facilitate composite scores to
more accurately capture the diversity functions of EF and their
relationships to symptoms, risk factors, and treatments. Finally,
to best inform on the state, trait, and scar debate, prospective
longitudinal studies should be done, measuring cognition before
the onset of MDD, and thus asses predisposing traits, and
potentially scarring effects of FE MDD not captured by the
current study.
CONCLUSION
The present study indicated that a group of former FE MDD
patients showed lasting, stable, deficits in cognition compared to
a healthy matched control group after 5 years. There were deficits
in both processing speed and EF. Findings suggest that processing
speed are related to depressive symptoms indicating state effects.
There was no clear worsening of cognitive function. Some aspects
of EF like Inhibition showed persistent deficits independent
of depressive symptom state, indicating trait effects. The study
underscores the importance of persisting cognitive residual
symptoms following FE MDD, and the need to adapt treatments
and prevention strategies targeting cognitive functioning.
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